Mural Oncology PLC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
SCHEDULE: Trium Capital Exits Mural Oncology Stake
Trium Capital LLP has filed an amended Schedule 13G, reporting a complete divestment of its beneficial ownership in Mural Oncology plc, now holding 0% of the ordinary shares.
SCHEDULE: Prosight Exits Mural Oncology Stake
Prosight Management and its affiliated funds have fully divested their beneficial ownership in Mural Oncology plc, reporting a 0% stake.
Soleus Capital Master Fund and its affiliates have reported a complete divestment of their beneficial ownership in Mural Oncology plc, now holding 0% of the company's ordinary shares.
Trium Capital LLP, a UK-based investment adviser, has reported a 10.16% beneficial ownership stake in Mural Oncology plc.
Armistice Capital and Steven Boyd have filed an amended Schedule 13G, reporting zero beneficial ownership in Mural Oncology plc's ordinary shares.
Solas Capital Management and Frederick Tucker Golden have fully divested their beneficial ownership in Mural Oncology plc, now holding 0% of ordinary shares.
Soleus Capital Master Fund and its affiliates have disclosed a 7.6% passive ownership stake in Mural Oncology PLC, holding 1,323,877 ordinary shares.
Prosight Management, LP and affiliated entities, including W. Lawrence Hawkins, have disclosed a passive beneficial ownership of 5.2% in Mural Oncology plc, totaling 900,000 ordinary shares.
Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Mural Oncology plc, holding 1,722,000 ordinary shares as of March 31, 2025.
Solas Capital Management, LLC and Frederick Tucker Golden have filed an amended Schedule 13G, disclosing a passive 5.2% beneficial ownership stake in Mural Oncology plc as of March 31, 2025.
Hudson View Holdings LLC, Hudson View Capital LLC, Stuart Feldman, and Matthew Barkoff have jointly disclosed a beneficial ownership of 5.55% in Mural Oncology plc's Ordinary Shares.
Soleus Capital Master Fund, along with its affiliated entities and Guy Levy, has reported a passive beneficial ownership of 6.3% in Mural Oncology PLC.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, revealing a beneficial ownership of 9.96% in Mural Oncology plc as of December 31, 2024.
Acorn Bioventures, L.P., along with its affiliates and manager Anders Hove, has disclosed a combined beneficial ownership of 7.6% in Mural Oncology plc, totaling 1,286,079 shares as of December 31, 2024.